Inhaled insulin Afrezza has launched in India, offering a needle-free option for diabetes management. Designed to overcome ...

Inhaled insulin, a patient-friendly alternative to injections, has been introduced in India. This new method aims to alleviate 'needle phobia' and improve diabetes management.

MannKind closed 2025 on a high note, marked by milestones that reinforce our growth trajectory—including the acquisition of scPharmaceuticals and a record-setting fourth quarter surpassing $100 ...

Investing.com -- MannKind Corporation (NASDAQ:MNKD) stock surged 10.9% Thursday after the company outlined several potential growth catalysts for 2026, including multiple FDA decisions and new product ...

Health system pharmacists and clinicians are monitoring a wave of drug approvals expected throughout 2026, including first-in-class therapies and expanded uses of existing drugs with implications for ...

H.C. Wainwright reiterated a ‘Buy’ rating on MannKind with an $11 price target after the company’s update. ・The firm said it ...

Researchers have found a new way to supply the body with insulin. The medication that can be taken orally has already been tested on baboons, in which it was found to lower the blood sugar levels ...

Lindsay Curtis is a health & medical writer in South Florida. She worked as a communications professional for health nonprofits and the University of Toronto’s Faculty of Medicine and Faculty of ...

This form of rapid-acting inhaled insulin, recently introduced in India by the name Afrezza, is said to offer an important ...